Healthcare research – understanding the Chinese regulatory framework

Richard Tadd Blog

China has always been an attractive destination for researchers in the healthcare sector because of its size and population, and the scale of studies thus made possible. Until recently, though, its regulatory system was cumbersome and not well designed for foreigners, who found it hard to understand what was required of them. Thankfully, the past couple of years have seen …

The developing biotech sector in China

Richard Tadd Blog

Twenty years ago, China’s biotech industry was worth around $2.4bn. This year, its revenues are expected to exceed $1.2tn. That’s a remarkable achievement by any standards, and one that has understandably led to excitement among investors and industry professionals alike. How has it been achieved? How has the sector actually changed and what can we expect to see in the …

Tackling the 2019-nCoV coronavirus – what the experts are doing

Richard Tadd Blog

The emergence of a new, potentially dangerous coronavirus in the city of Wuhan in China’s Hubei province has sparked a flurry of articles in the international media and widespread discussion on social media, much of it poorly informed or coloured by politics. With epidemiologists from multiple nations working together to tackle the outbreak, cooperation and the clear exchange of information …

Real-world evidence regulations are on the way

Richard Tadd Blog

The last decade has seen increasing emphasis worldwide on the importance of well-regulated, real-world data collection and analysis as a follow-up to clinical trials for new medicines and medical devices. China is now taking steps to make regulatory changes of its own in this area. On 7 January 2020, the National Medical Products Association (NMPA) released a paper entitled Guiding …